Ipamorelin typical research dosing
Across the available literature, Ipamorelin is most commonly administered at 100–300 mcg per dose, 2 time(s) per day, via subcutaneous injection. Research protocols frequently use 100–300 mcg, 2–3× daily, with pre-bed dosing emphasized to support natural overnight GH release.
Ipamorelin unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 5 mg Ipamorelin vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 100 mcg | 200 mcg | 300 mcg |
|---|---|---|---|---|
| 1 mL | 5000 mcg/mL | 2.0 units | 4.0 units | 6.0 units |
| 2 mL | 2500 mcg/mL | 4.0 units | 8.0 units | 12.0 units |
| 3 mL | 1667 mcg/mL | 6.0 units | 12.0 units | 18.0 units |
| 5 mL | 1000 mcg/mL | 10.0 units | 20.0 units | 30.0 units |
Ipamorelin cycle length
Most reported Ipamorelin protocols run 8 weeks on, then 4 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Ipamorelin half-life and timing
Ipamorelin has a half-life of approximately 2 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.